Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma|Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
Interventions: BIOLOGICAL: mRNA-2752|BIOLOGICAL: Durvalumab
Sponsor: ModernaTX, Inc.
Collaborators: AstraZeneca